Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(6):405; doi:10.1093/jnci/94.6.405
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 94, No. 6, 405, March 20, 2002
© 2002 Oxford University Press

IN THIS ISSUE

COX-2 Inhibition and Barrett’s Esophagus

Although the mechanisms responsible for the progression from Barrett’s esophagus to esophageal adenocarcinoma are unclear, it has been postulated that mucosal injury associated with gastric reflux induces the synthesis of prostaglandins and mediators of inflammation. Because cyclooxygenase (COX)-2 is the rate-limiting enzyme involved in prostaglandin synthesis, Buttar et al. (p. 422) examined the effect of inhibiting COX-2 activity in primary cultures of Barrett’s esophageal cells. With the use of the selective COX-2 inhibitor NS-398, the authors studied changes in the proliferation of Barrett’s esophageal epithelial cells. They found that inflammatory cytokines had little . . . [Full Text of this Article]

Quality of Life After Androgen Deprivation Therapy

Calcium Intake and Risk of Colon Cancer

p16 and Melanocyte Senescence

Growth Hormone Genes and Colorectal Cancer

Intratumoral Lymphangiogenesis